We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Argos Therapeutics has announced the initiation of a Phase I/II clinical trial to test the immunologic activity and safety of its AGS-004 in HIV-infected adults.
Zelos Therapeutics has announced top-line results from a Phase II study of its novel parathyroid hormone (PTH) analogue, Ostabolin-C, in postmenopausal women with osteoporosis.
Anesiva has presented positive data from a Phase II trial in total knee replacement surgeries with drug candidate 4975, the company's novel, long-acting, non-opioid drug being developed for site-specific, moderate-to-severe pain.
Bayer Pharmaceuticals and Onyx Pharmaceuticals announced that an independent data monitoring committee (DMC) has reviewed the safety and efficacy data from the companies' pivotal Phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer.
Mylan Pharmaceuticals has received final approval from the FDA for its abbreviated new drug application (ANDA) for sotalol hydrochloride tablets, 80, 120 and 160 mg.
A handful of drugmakers announced they have won FDA approval to market generic versions of Pfizer's antidepressant Zoloft. The companies include Mylan, Lupin, Roxane, Actavis, Pliva and Ranbaxy.
Pro-Pharmaceuticals announced it has begun the process of submitting a new drug application to the FDA for co-administration of Davanat with 5-Fluorouracil (5-FU) for treatment in cancer patients.